Since 2016, Low Dose Naltrexone has been most commonly used to treat such ailments as Multiple Sclerosis, Chronic Fatigue, and Myalgic Encephalopathy, as well as various cancers and autoimmune thyroid diseases. Autoimmune diseases, in particular, seem to respond well to it.
The FDA first approved the drug in 1984. At the time, it was introduced in a 50 mg dose, its purpose being to help heroin and opium addicts. It was ideal for this use since it blocks the effects of such drugs. Naltrexone blocks opioid receptors, while at the same time preventing the reception of beta-endorphins and metenkephalin, the opioid hormones that the adrenal glands and the brain produce. Lots of body tissues have receptors for these enkephalins and endorphins, including essentially each cell of the body’s immune system.
In 1985, Bernard Bihari, MD, working out of a clinical practice in New York City, realized that the effects of a much smaller dose of the drug (approximately 3 mg once each day), was able to enhance a patient’s response to HIV infection.
By the mid-1990s, Dr. Bihari discovered that patients in his practice with cancer (such as pancreatic or lymphoma), could benefit quite a bit in some cases from Low Dose Naltrexone. He also found that people who had an autoimmune disease like lupus showed rapid control of disease activity when put on the drug.
Over the past twenty years, a great deal of research has been done on Low Dose Naltrexone. It has been determined that the body’s endorphin secretions (our internal opioids) play a central role in beneficial orchestration of the immune system. Recognition of this has become widespread.
In a November 13, 2003 issue of the New England Journal of Medicine, it was noted that "Opioid-Induced Immune Modulation:... Preclinical evidence indicates overwhelmingly that opioids alter the development, differentiation, and function of immune cells, and that both innate and adaptive systems are affected.1,2 Bone marrow progenitor cells, macrophages, natural killer cells, immature thymocytes and T cells, and B cells are all involved. The relatively recent identification of opioid-related receptors on immune cells makes it even more likely that opioids have direct effects on the immune system."
When you take Low Dose Naltrexone before bed each night, it is believed that it produces a temporary inhibition of endorphins. An up-regulation of vital elements of the immune system is the result. There is an increase in enkephalin and endorphin production, as well as increased opioid receptor sensitivity and opioid receptor production. Healthy volunteers who have taken the drug in this fashion have seen their levels of beta-endorphins circling in the blood rise in the following days. Animal research was also conducted by I. Zagon, PHD. He and his colleagues noted a marked increase in metenkephalin levels there as well. Such elevated levels will usually last for about 18-20 hours.
The disorders listed all share a notable feature: the immune system plays a central role in each of them. Low blood levels of endorphins are usually present, which contributes to the disease-associated immune deficiencies. Such findings suggest that the chance of a beneficial Low Dose Naltrexone effect in a wide variety of autoimmune diseases and common cancers is high.
- Bladder Cancer
- Breast Cancer
- Colon & Rectal
- Liver Cancer
- Lung Cancer (Non-Small Cell)
- Lymphocytic Leukemia (chronic)
- Malignant Melanoma
- Multiple Myeloma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer (untreated)
- Renal Cell Carcinoma
- Throat Cancer
- Uterine Cancer
- Lymphoma (Hodgkin's and Non-Hodgkin's)
- Autoimmune Neurodegenerative
- ALS (Lou Gehrig's Disease)
- Alzheimer's Disease
- Autism Spectrum Disorders
- Hereditary Spastic Paraparesis
- Multiple Sclerosis (MS)
- Parkinson's Disease
- Post-Traumatic Stress Disorder (PTSD)
- Primary Lateral Sclerosis (PLS)
- Progressive Supranuclear Palsy Transverse Myelitis
- Common Cold (URIs)
- Emphysema (COPD)
- Depression (Major; and Bipolar)
- Ankylosing Spondylitis
- Behcet's Disease
- Celiac Disease
- Chronic Fatigue Syndrome
- CREST syndrome
- Crohn's Disease
- Hashimotos Thyroiditis
- Irritable Bowel Syndrome (IBS)
- Myasthenia Gravis (MG)
- Nephrotic Syndrome
- Primary Biliary Cirrhosis
- Rheumatoid Arthritis
- Sjogrens Syndrome
- Stiff Person Syndrome (SPS)
- Systemic Lupus (SLE)
- Ulcerative Colitis
- Wegener's Granulomatosis
Controlled clinical trials of Low Dose Naltrexone in the treatment of cancer have not yet been accomplished. However, as of March 2004 clinical “off-label” use of the medication by Dr. Bihari in some 450 patients with cancer revealed that more than 60% of them saw some benefit from it. These were patients who had not responded to standard treatments.
Dr. Bihari had follow-ups with 354 of these patients and found that 86 of them had significant shrinkage of tumors, at least a 75% reduction. 125 patients had stabilized or were moving toward remission.
The results attained by Dr. Bihari contrasted with usual cancer treatment outcomes, those being death from cancer or a total cure. It therefore is reasonable to surmise that Low Dose Naltrexone treatments represent a viable third alternative, the gradual reduction of tumor mass volume or possible long-term stabilization.
None of Dr. Bihari’s group of patients who presented with autoimmune diseases have failed to respond to treatment with Low Dose Naltrexone. All of them have experienced a halt in the progression of their conditions. In several of these patients, there has been a marked remission in symptoms and signs of the disease. Many of those in the autoimmune group have multiple sclerosis; there were 400 in Dr. Mihari’s practice. The doctor reported that less than 1% of those 400 experienced a fresh attack of MS while they were kept on nightly therapy with Low Dose Naltrexone.
The treatment of AIDS/HIV has also seen the use of Low Dose Naltrexone since the 1980s, with good effect. There are a score of these patients who even today only use Low Dose Naltrexone and can keep the virus in check. Low Dose Naltrexone, when combined with HAART, is a total preventative for lipodystrophy. It is also a synergistic therapy that bolsters the restoration of CD4 cell levels and diminishes viral breakdowns. As of September 2003, Dr. Bihari treated 350 AIDS patients using Low Dose Naltrexone along with accepted AIDS therapies. Over the seven years before that, he reported that over 85% percent of his patients showed no detectable signs of HIV. This was a much higher success rate than most current AIDS treatments, and there were also no significant side effects. Many HIV/AIDS patients have also been living symptom-free for years at this point by taking only Low Dose Naltrexone with no other medications.
In May of 2016, Nigeria approved a prescribed version of Low Dose Naltrexone for HIV. There was a very successful three-month bridge trial that was performed by NAFDAC, which is Nigeria’s equivalent to the FDA. Approval is currently being granted to Immune Therapies Inc., formerly called TNIB, to market Lodonal (Low Dose Naltrexone) as a non-toxic adjunct therapy for the treatment of HIV/AIDS as well as an immune system regulator. There are also anecdotal reports that indicate that Low Dose Naltrexone can be beneficial for those dealing with primary lateral sclerosis, Alzheimer's Disease, Parkinson's Disease, and ALS, also known as Lou Gehrig’s Disease. Dr. Jaquelyn McCandless has also found that Low Dose Naltrexone in an appropriately reduced dosage when applied as a transdermal cream can be helpful for children with autism.
Treatment doses usually begin in the range of 0.5 to 1.5 mg. Once the dosage has started to be taken on a nightly basis, it is often brought up to 4.5 mg. Low Dose Naltrexone is best taken between 9 pm and 3 am because of the rhythm of the body’s production of master hormones. Most patients take it before going to bed.
- For Fibromyalgia, Chronic Fatigue Syndrome, or Hashimoto's Thyroiditis, the starting dose is typically 0.5 mg every week until the daily dose of 4.5 mg is reached.
- In the case of autoimmune diseases, patients typically begin with 1 mg doses and increase to 4.5 mg over four weeks.
- Those with Multiple Sclerosis who are dealing with muscle spasms are advised to start with 3 mg per day and to maintain that dosage.
- Those with hyperthyroidism, Hashimoto's Thyroiditis, and those who are taking thyroid hormone replacement medication as well as Low Dose Naltrexone should pay attention to the warnings below.
- Those with cancer who are using Low Dose Naltrexone can take similar doses, but these must be avoided the weeks before or after chemotherapy. This does not include daily medications for prostate cancer and tamoxifen.
The range of therapeutic dosages for Low Dose Naltrexone is 1.5 to 4.5 mg every night. Dosages below this range will probably be ineffective. Dosages of more than this amount will likely block the endorphins for too long of a period and the drug will not be as effective.
- Capsules - It is critical to remember that Low Dose Naltrexone should not be prescribed in SR or slow release form. The capsules should also be filled with a neutral, inactive filler such as lactose or avicel.
- Sublingual Drops - Occasionally the drug will need to be purchased as a solution in distilled water. In these cases, 1 mg/ml will be dispensed in a medicine dropper. The solution must be refrigerated.
- Cream - Low Dose Naltrexone can also be administered in a 0.5 mg /ml dose as a cream that's applied to the skin. This is most helpful for children or patients who have allergies to colors, excipients, or flavorings found in other forms of Low Dose Naltrexone.
There are virtually no side effects that have been reported with the use of Low Dose Naltrexone. On occasion during the first week of use patients may have a little difficulty sleeping. This rarely persists beyond the first week. If this is a problem, then the dosage can be reduced from 4.5 mg down to 3.
1. Low Dose Naltrexone blocks opioid receptors in the body for 3-4 hours. People who are using medicine that is an opioid agonist, i.e. a narcotic medication like Percocet, a Duragesic patch, Ultram (tramadol) or a codeine-containing medication should not take Low Dose Naltrexone until such drugs are entirely out of their system. Patients who have developed a dependence on daily use of narcotic-containing pain medication will likely require ten days to 2 weeks to be weaned off such drugs entirely before they can safely begin to take Low Dose Naltrexone. During this time they can substitute full doses of non-narcotic pain medications.
2. Patients who take thyroid hormone replacement for Hashimoto's thyroiditis with hypothyroidism should start taking the lowest dosage of Low Dose Naltrexone, 1.5 mg for an adult. Low Dose Naltrexone can lead to a swift decrease in the autoimmune disorder. If this takes place, a rapid reduction in the dose of thyroid hormone replacement will be necessary to avoid the symptoms of hyperthyroidism.
3. Full-dose Naltrexone, or 50 mg, carries a cautionary warning related to the possibility of liver disease. This warning is in place because adverse liver effects have been found in experiments where a dose of 300 mg was administered daily. The 50 mg dosage does not produce this effect, nor do the smaller dosages of 3 mg and 4.5 mg.
4. People who have received transplanted organs and who are taking immunosuppressive medications permanently are cautioned against the use of Low Dose Naltrexone. It can counteract the effects of such drugs.
5. In lots of cases, Low Dose Naltrexone is taken along with standard multiple sclerosis medications. All of the conventional MS drugs, though, with the probable exception of Copaxone, are immunosuppressant. Because of this, they are likely to oppose the effects of Low Dose Naltrexone. Many people with MS therefore try to wean themselves off of these other medications if they find that Low Dose Naltrexone is having a positive effect for them.
Presented material taken directly from:
- Roy S, Loh HH. Effects of opioids on the immune system. Neurochem Res 1996;21:1375-1386
- Risdahl JM, Khanna KV, Peterson PK, Molitor TW. Opiates and infection. J Neuroimmunol 1998;83:4-18
- Makman MH. Morphine receptors in immunocytes and neurons. Adv Neuroimmunol 1994;4:69-82